(Reuters) - Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available ...

After she was diagnosed at age 48 with Type 1 diabetes, Stacey Silverman muddled through her days with high blood sugar, fatigue and splitting headaches. Taking a long-acting form of insulin called ...

Levemir, one of the three types of long-acting basal insulins, is evacuating the U.S. market, and diabetes patient advocates told USA Today they’re worried about using a new medication after nearly ...

Novo Nordisk (NVO) is reportedly set to meet with U.S. Senate aides on Tuesday to discuss why the drugmaker is discontinuing marketing its long-acting insulin Levemir in the U.S. The Danish drugmaker ...

As a special education teacher living with Type 1 diabetes in Crawfordsville, I’ve relied on insulin to manage my condition since my diagnosis in 2011. Despite my engagement as an #insulin4all ...

A year ago, when Novo Nordisk announced it would cut the price of multiple insulin products by up to 75%, President Biden, lawmakers, and patient groups all counted the move as a win. But several ...

Novo Nordisk maintains that patients have ample time to transition to other options. Novo Nordisk, Eli Lilly, and Sanofi control 100% of the insulin market in the U.S Get two weeks of free access to ...

COPENHAGEN, June 26 (Reuters) - Danish Novo Nordisk said on Friday its insulin drug Levemir received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) for ...

COPENHAGEN, Oct 22 (Reuters) - Denmark's Novo Nordisk , the world's biggest maker of insulin, said on Monday Japanese health authorities have approved it long-acting insulin Levemir for use in type 1 ...